Cue Biopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Cue Biopharma, Inc. (CUE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 113.68 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-14
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 488.00 shares, a 99.97% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 113.20K shares, a 401.69% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 1.02M shares, a 201.49% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 160.49K shares, a 71.91% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 2.71M shares, a 93.16% increase from fiscal 2024.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.40M shares, a 26.85% increase from fiscal 2023.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.11M shares, a 258.56% increase from fiscal 2022.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 308.80K shares, a 25.78% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 488.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 113.68K shares 10-Q · filed 2026-08-14 | 1.14M shares derived: sum of 3 quarters · filed 2026-08-14 | 1.30M shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 113.20K shares 10-Q · filed 2026-05-14 | 1.14M shares derived: sum of 2 quarters · filed 2026-05-14 | 1.30M shares derived: sum of 3 quarters · filed 2026-05-14 | 2.80M shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 1.02M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 1.19M shares derived: sum of 2 quarters · filed 2026-03-16 | 2.69M shares derived: sum of 3 quarters · filed 2026-03-16 | 2.71M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 160.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.67M shares derived: sum of 2 quarters · filed 2025-11-12 | 1.69M shares 10-Q · filed 2025-11-12 | 2.03M shares derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-06-30 | 1.51M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 1.53M shares 10-Q · filed 2025-08-12 | 1.87M shares derived: sum of 3 quarters · filed 2026-03-16 | 2.44M shares derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-03-31 | 22.56K shares 10-Q · filed 2025-05-12 | 362.46K shares derived: sum of 2 quarters · filed 2026-03-16 | 933.75K shares derived: sum of 3 quarters · filed 2026-03-16 | 1.34M shares derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | 339.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 911.18K shares derived: sum of 2 quarters · filed 2026-03-16 | 1.31M shares derived: sum of 3 quarters · filed 2026-03-16 | 1.40M shares 10-K · filed 2026-03-16 |
| 2024-09-30 | 571.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 972.85K shares derived: sum of 2 quarters · filed 2024-11-14 | 1.06M shares 10-Q · filed 2024-11-14 | 1.09M shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | 401.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 493.31K shares 10-Q · filed 2024-08-14 | 515.87K shares derived: sum of 3 quarters · filed 2025-03-31 | 1.24M shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | 91.75K shares 10-Q · filed 2024-05-09 | 114.31K shares derived: sum of 2 quarters · filed 2025-03-31 | 833.51K shares derived: sum of 3 quarters · filed 2025-03-31 | 883.43K shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | 22.56K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 741.76K shares derived: sum of 2 quarters · filed 2025-03-31 | 791.68K shares derived: sum of 3 quarters · filed 2025-03-31 | 1.11M shares 10-K · filed 2025-03-31 |
| 2023-09-30 | 719.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 769.12K shares derived: sum of 2 quarters · filed 2023-11-03 | 1.08M shares 10-Q · filed 2023-11-03 | 1.18M shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-06-30 | 49.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 365.49K shares 10-Q · filed 2023-08-08 | 460.35K shares derived: sum of 3 quarters · filed 2024-03-28 | 510.48K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-03-31 | 315.57K shares 10-Q · filed 2023-05-09 | 410.43K shares derived: sum of 2 quarters · filed 2024-03-28 | 460.55K shares derived: sum of 3 quarters · filed 2024-03-28 | 516.61K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-12-31 | 94.86K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 144.99K shares derived: sum of 2 quarters · filed 2024-03-28 | 201.05K shares derived: sum of 3 quarters · filed 2024-03-28 | 308.80K shares 10-K · filed 2024-03-28 |
| 2022-09-30 | 50.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 106.19K shares derived: sum of 2 quarters · filed 2022-11-14 | 213.94K shares 10-Q · filed 2022-11-14 | 243.31K shares derived: sum of 4 quarters · filed 2023-03-21 |
| 2022-06-30 | 56.06K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 163.81K shares 10-Q · filed 2022-08-04 | 193.19K shares derived: sum of 3 quarters · filed 2023-03-21 | 265.97K shares derived: sum of 4 quarters · filed 2023-03-21 |
| 2022-03-31 | 107.75K shares 10-Q · filed 2022-05-10 | 137.13K shares derived: sum of 2 quarters · filed 2023-03-21 | 209.91K shares derived: sum of 3 quarters · filed 2023-03-21 | 323.26K shares derived: sum of 4 quarters · filed 2023-03-21 |
| 2021-12-31 | 29.38K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | 102.16K shares derived: sum of 2 quarters · filed 2023-03-21 | 215.51K shares derived: sum of 3 quarters · filed 2023-03-21 | 245.51K shares 10-K · filed 2023-03-21 |
| 2021-09-30 | 72.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 186.14K shares derived: sum of 2 quarters · filed 2021-11-09 | 216.14K shares 10-Q · filed 2021-11-09 | 324.57K shares derived: sum of 4 quarters · filed 2022-03-16 |
| 2021-06-30 | 113.36K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 143.36K shares 10-Q · filed 2021-08-09 | 251.79K shares derived: sum of 3 quarters · filed 2022-03-16 | 419.14K shares derived: sum of 4 quarters · filed 2022-03-16 |
| 2021-03-31 | 30.00K shares 10-Q · filed 2021-05-10 | 138.44K shares derived: sum of 2 quarters · filed 2022-03-16 | 305.78K shares derived: sum of 3 quarters · filed 2022-03-16 | |
| 2020-12-31 | 108.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | 275.78K shares derived: sum of 2 quarters · filed 2022-03-16 | 289.66K shares 10-K · filed 2022-03-16 | |
| 2020-09-30 | 167.34K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 181.22K shares 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | 13.88K shares 10-Q · filed 2020-08-07 | |||
| 2019-12-31 | 1.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | 103.56K shares derived: sum of 2 quarters · filed 2021-03-09 | 535.69K shares derived: sum of 3 quarters · filed 2021-03-09 | 550.06K shares 10-K · filed 2021-03-09 |
| 2019-09-30 | 102.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 534.56K shares derived: sum of 2 quarters · filed 2019-11-07 | 548.94K shares 10-Q · filed 2019-11-07 | 566.44K shares derived: sum of 4 quarters · filed 2020-03-12 |
| 2019-06-30 | 432.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 446.50K shares 10-Q · filed 2019-08-08 | 464.00K shares derived: sum of 3 quarters · filed 2020-03-12 | 464.00K shares derived: sum of 4 quarters · filed 2020-03-12 |
| 2019-03-31 | 14.38K shares 10-Q · filed 2019-05-08 | 31.88K shares derived: sum of 2 quarters · filed 2020-03-12 | 31.88K shares derived: sum of 3 quarters · filed 2020-03-12 | |
| 2018-12-31 | 17.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | 17.50K shares derived: sum of 2 quarters · filed 2020-03-12 | 25.00K shares 10-K · filed 2020-03-12 | |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | 7.50K shares 10-Q · filed 2018-11-13 | ||
| 2018-06-30 | 7.50K shares 10-Q · filed 2018-08-13 | |||
| 2017-12-31 | 17.20K shares 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |